Hybrigenics General Meetings
Only the french version of documents is available
Shareholders
Institutional Shareholders Since its creation 1997, the company gathered € 58 millions, in three steps.
The first step was made with Venture Capital funds, Apax being one of them since the beginning. In three rounds, € 49 millions were raised, which were invested in the growth of the company.
The second step occurred in December 2007, when the company went public after an IPO on Alternext, with 6.2 millions raised.
The last step was a private placement with qualified investors, for € 2.8 millions in December 2009.
Advent Management Belgium is one of the most prominent private equity investors in Belgium. Advent manages the independent Sofindev funds that provide expansion financing or replacement capital. Alafi CapitalAlafi Capital is a private venture capital company mainly specialized in life sciences market, investing primarily in the USA but also in several European countries. Alafi Capital ususually invest at very early stage, and maintains its investment in Companies up stock-market listing and beyond. The track record of Alafi Capital is probably one of the best in the world, having been at the origin of several of todays industrial leaders in Biotechnology, including Amgen, Biogen, Cetus (now part of Chiron), Cooley Pharmaceuticals, Genelabs, Molecular Devices, Molecular Dynamics, , Oxford Glycosciences (UK) Qiagen (Germany) etc… Apax Partners is one of the world's leading private equity investment firms. Apax is dedicated to helping entrepreneurs build world class companies. The company track record of working with entrepreneurs from start up to leveraged transactions of over Euro 1 billion is exceptional. Since 1995 alone 46 of their companies went public on stock markets around the world. At point of entry to market these companies had a collective market capitalisation of over Euro 23 billion. Apax Partners currently has Euro 12 billion under management or advice around the world, and 330 companies in the portfolio. Apax 160 investment professionals operate from twelve offices in nine countries. AVIDA Group is an independent private equity management group that manages and supports pan-European private equity funds with aggregate capital commitments amounting to more than EUR 460 million. In addition to initiating and managing its own private equity funds, AVIDA Group is specialized in Secondary Management and Private Equity Advisory. Life Sciences Partners is a European venture capital firm based in Amsterdam (Netherlands) and Munich (Germany), focusing on human biotechnology and medical devices. The fund has € 170 million capital under management and has invested in a broad range of companies in Europe, the US and Israel. The partners of the fund have a proven track record in venture capital and the life sciences, among others through Board Seats at listed companies as Qiagen, Quadrant, Rhein Biotech, Biora and Crucell. Medicis provides venture capital to innovative teams and companies in the Life Science and Healthcare market. Their mission is to provide their market know how as well as their distinctive financial and business network to young and innovative companies employing cutting edge life science technologies or novel health care management concepts and/or systems. Jointly with their portfolio companies they strive to improve the quality and efficiency of the life science and healthcare market.
Rendex PartnersRendex Partners is a European based private equity fund, managing Rendex Fund, a venture capital fund investing in growth opportunities in industry ranging from high tech to no-tech.
|
